von Tresckow, Bastian, Fanale, Michelle, Ardeshna, Kirit M., Chen, Robert, Meissner, Julia, Morschhauser, Franck, Moskowitz, Craig, Zinzani, Pier Luigi, Giezek, Hilde, Balakumaran, Arun, Vo, Thao T., Raut, Monika and Brice, Pauline (2019). Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma. Leuk. Lymphoma, 60 (11). S. 2705 - 2712. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Full text not available from this repository.

Abstract

In KEYNOTE-087, pembrolizumab had a 69% overall response rate and acceptable safety in patients with relapsed/refractory classical Hodgkin lymphoma (rrHL). We assessed health-related quality of life (HRQoL) in KEYNOTE-087. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and the EuroQoL Five Dimensions Questionnaire 3-level version (EQ-5D) were administered to 206 patients across three cohorts defined by lymphoma progression after: (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV) (n = 69); (2) salvage chemotherapy and BV (n = 79); and (3) ASCT without post-transplantation BV (n = 58). Compliance/completion rates were >= 90% at week 12 and >= 70% at week 24. QLQ-C30 global health status/QoL and EQ-5D visual analog scale scores showed mean increases from baseline in overall health at all assessed timepoints. With few exceptions, mean improvements from baseline to weeks 12 and 24 in QLQ-C30 functional and symptom scores occurred in all cohorts.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
von Tresckow, BastianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fanale, MichelleUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ardeshna, Kirit M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Chen, RobertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Meissner, JuliaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Morschhauser, FranckUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Moskowitz, CraigUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zinzani, Pier LuigiUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Giezek, HildeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Balakumaran, ArunUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vo, Thao T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Raut, MonikaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brice, PaulineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-141125
DOI: 10.1080/10428194.2019.1602262
Journal or Publication Title: Leuk. Lymphoma
Volume: 60
Number: 11
Page Range: S. 2705 - 2712
Date: 2019
Publisher: TAYLOR & FRANCIS LTD
Place of Publication: ABINGDON
ISSN: 1029-2403
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
CANCER; PD-L1; EQ-5D; EORTCMultiple languages
Oncology; HematologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/14112

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item